Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2026)
Aurinia Pharmaceuticals (AUPH) posted EBT Margin of 56.53% for Q1 2026, up 22.14% on a QoQ basis from 46.28% in Q4 2025, and up 1755.0% year-over-year from 3.05% in Q1 2025.
Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' EBT Margin history runs 8 years deep, the most recent figure standing at 56.53% for Q1 2026.
- Quarterly EBT Margin rose 1755.0% year-over-year to 56.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.83% (up 2793.0% YoY) and the FY2025 annual result came in at 40.33%, up 3716.0% from the prior year.
- EBT Margin was 56.53% for Q1 2026 at Aurinia Pharmaceuticals, up from 46.28% in the prior quarter.
- Across five years, EBT Margin topped out at 56.53% in Q1 2026 and bottomed at 173.97% in Q1 2022.
- A 5-year average of 21.55% and a median of 14.41% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 533709 bps — and 2023, when it plunged 971 bps.
- Aurinia Pharmaceuticals' EBT Margin stood at 88.59% in 2022, then surged by 34 bps to 58.58% in 2023, then jumped by 103 bps to 1.96% in 2024, then surged by 2262 bps to 46.28% in 2025, then climbed by 22 bps to 56.53% in 2026.
- Business Quant data shows AUPH's EBT Margin at 56.53% in Q1 2026, 46.28% in Q4 2025, and 43.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 56.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.53% |
| Dec 31, 2025 | 46.28% |
| Sep 30, 2025 | 43.50% |
| Jun 30, 2025 | 31.65% |
| Mar 31, 2025 | 38.98% |
| Dec 31, 2024 | 1.96% |
| Sep 30, 2024 | 21.85% |
| Jun 30, 2024 | 2.58% |
| Mar 31, 2024 | -19.90% |
| Dec 31, 2023 | -58.58% |
| Sep 30, 2023 | -24.12% |
| Jun 30, 2023 | -29.24% |
| Mar 31, 2023 | -74.89% |
| Dec 31, 2022 | -88.59% |
| Sep 30, 2022 | -14.41% |
| Jun 30, 2022 | -125.95% |
| Mar 31, 2022 | -173.97% |
| Dec 31, 2021 | -139.28% |
| Sep 30, 2021 | -342.59% |
| Jun 30, 2021 | -709.85% |